Coya Therapeutics (COYA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 May, 2026Executive summary
Annual meeting scheduled for June 25, 2026, to be held virtually at 12:00 p.m. C.T.
Proxy materials and annual report for the year ended December 31, 2025, are available online for review and voting.
Shareholders are encouraged to review all proxy materials before voting and can opt for electronic delivery to support environmental initiatives.
Voting matters and shareholder proposals
Election of two directors: Wilbur Ross and Dieter Weinand, with board recommending a vote FOR both.
Ratification of Weaver and Tidwell, L.L.P. as independent registered public accounting firm for the year ending December 31, 2026, recommended by the board.
Board of directors and corporate governance
Board of Directors has provided recommendations for all voting items, supporting all nominees and auditor ratification.
Latest events from Coya Therapeutics
- Treg-based therapies show promise in ALS and FTD, with key Phase 2 data expected in 2027.COYA
Investor presentation - Q2 2026 net loss rose to $6.6M as R&D spending increased and $43.2M cash remained.COYA
Q2 2026 - COYA 302 advances to phase 2B ALS trial, with major data and partnership milestones set for 2025.COYA
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 - Treg-targeted therapies advance in ALS and FTD, with pivotal data expected in 2027.COYA
Investor presentation - Board elections, auditor ratification, and clinical milestones highlighted; all proposals approved.COYA
AGM 2026 - Inflammation-driven brain injury from repetitive trauma is a major public health concern.COYA
Investor update - Advancing Treg-targeted therapies for neurodegeneration with pivotal trials and strong partnerships.COYA
Investor presentation - Virtual meeting to elect directors and ratify auditor, with strong governance and compensation policies.COYA
Proxy filing - Q1 2026 saw FDA Fast Track, narrowed net loss, and $50.7M cash runway into H2 2027.COYA
Q1 2026